Leap In Molecular Diagnostics Attributed To AI System

Seegene, a developer of multiplex PCR technologies, using a unique artificial intelligence ("AI") based assay development system, has developed molecular diagnostics ("MDx") assays in four (4) days. The assays are high multiplex real-time PCR reagents developed in their entirety by AI and are designed to simultaneously detect eight different DNA targets for each of meningitis and sexually transmitted infections.


The company confirms the performance (sensitivity and specificity) of the assays developed by AI are equivalent to or even better than that of those manually developed and only four (4) days were sufficient to successfully develop two 8-plex assays, while more than a year was required by a team of experienced professionals.

Free Newsletter

Like this article? Subscribe to FierceSensors!

The sensors industry is constantly changing as innovation runs the market’s trends. FierceSensors subscribers rely on our suite of newsletters as their must-read source for the latest news, developments and analysis impacting their world. Register today to get sensors news and updates delivered right to your inbox.


The AI-based automated assay development system, called the "Seegene Digitalized Development System (SG-DDS)", automates real-time PCR assay development utilizing big data of causative agents for diseases, Seegene's novel algorithms, and in silico oligonucleotide design with virtual experiments. This advancement significantly reduces the time and labor required for R&D and simplifies complicated real time PCR assay development processes, allowing non-professionals to easily develop multiplex MDx assays of their desire.


With SG-DDS, Project 100 will be completed to significantly increase the number of CE marked Allplex assays within this year. The pipeline includes assays that diagnose not only infectious diseases but also drug resistant, genetic disorders and various cancers including lung, breast and colon cancers.


Seegene's current business focus is the human IVD market, but the company is also preparing to pioneer non-human IVD areas as well. For its future assay portfolio, Seegene has included food safety, agriculture, aquaculture, animal health and other non-human related diagnostic assays to expand its already vast offerings. Further, Seegene plans to develop customized assays that can meet varied needs. More scintillating info is available, acquirable by visiting Seegene.


Suggested Articles

Annual growth of 15% is expected for next decade according to Future Market Insights

New tech relies on time-of-flight sensor tech used in HoloLens combined with CMOS

Edge computing has been around for a while, but the intelligent edge? Ah, come on!